{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Mesh Reinforcement in Stapled Left Pancreatectomy"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "single-blinded, parallel-group, randomised controlled trial included patients eligible for left pancreatectomy"
      },
      "Participants": {
        "score": 2,
        "evidence": "Conducted at a large tertiary hospital, this single-blinded, parallel-group, randomised controlled trial included patients eligible for left pancreatectomy."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised intraoperatively to receive either mesh reinforcement (Seamguard\u00ae or Peristrips Dry\u00ae) or no mesh reinforcement."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to assess the effectiveness of mesh reinforcement in reducing the incidence of clinically significant pancreatic leaks."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the incidence of clinically significant pancreatic leaks, defined by the ISGPF grading system, over a 6-week period."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was achieved using a computer-generated sequence with allocation concealment."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Patients were blinded to their group allocation."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 100 patients were randomised: 54 to the mesh group and 46 to the control group."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "The analysis was conducted on an intention-to-treat basis."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "ISGPF grade B and C leaks were observed in 1.9% (1/53) of patients in the mesh group compared to 20% (11/45) in the control group (p=0.0007)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No significant adverse events were reported in either group."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "The trial is registered at Clinicaltrials.gov (NCT01359410)."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 21,
    "max_score": 25
  },
  "model": "gpt-4o"
}